MRGFUS IN THE BRAIN

Focused ultrasound under magnetic resonance guidance for targeted drug delivery in the brain

 Coordinatore STICHTING KATHOLIEKE UNIVERSITEIT 

 Organization address address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ

contact info
Titolo: Mr.
Nome: Maarten
Cognome: Van Langen
Email: send email
Telefono: +31 243619791

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 259˙745 €
 EC contributo 259˙745 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-IOF
 Funding Scheme MC-IOF
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-09-01   -   2016-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT

 Organization address address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ

contact info
Titolo: Mr.
Nome: Maarten
Cognome: Van Langen
Email: send email
Telefono: +31 243619791

NL (NIJMEGEN) coordinator 259˙745.10

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

options    receive    drugs    blood    get    effectiveness    induced    clinical    combined    technique    tumour    fus    bbb    survival    breast    cancer    permeabilization    metastases    rats    agents    treatment    brain    patients    barrier    limited    animal   

 Obiettivo del progetto (Objective)

'Patients with brain tumours have limited treatment options and could benefit from new treatments. Focused ultrasound (FUS) combined with a microbubble agent, under guidance of magnetic resonance (MR) imaging, has been used in animal studies to temporarily open the blood-brain-barrier (BBB). The BBB normally protects the brain by blocking most substances from the blood and is a hurdle to the use of therapeutic agents in the brain. The ability to use FUS induced BBB disruption to target drugs to desired volumes in the brain presents a potentially huge advance for neuroscience. The method can also increase the permeability of the blood-tumour barrier, which often retains many characteristics of the normal BBB. To translate this technique to clinical applications, the effectiveness of the technique should be demonstrated. Patients with no or limited treatment options are probably the most willing candidates to participate in a clinical trial, e.g. breast cancer patients with brain metastases. For extracranial metastases in breast cancer patients two antibody agents have shown good results. Their effectiveness in brain metastases is limited, due to the BBB. Permeabilization of the BBB might improve survival in this group of patients. Animal studies with these drugs will be performed to study the survival and tumour progression in rats. The rats will be divided in different treatment groups, animals that 1) get one or both drugs combined with FUS induced BBB permeabilization; 2) only get one or both drugs; 3) only receive FUS induced BBB permeabilization; and 4) receive no treatment. The results of this project will guide future clinical studies. MRguided FUS for targeted drug delivery in the brain is a new and revolutionary technique, with possibilities in many diseases of the central nervous system. As there is limited research in Europe involving this technique, it is important for the ERA to increase the knowledge in Europe and expand research on this topic.'

Altri progetti dello stesso programma (FP7-PEOPLE)

EGGALL (2009)

Use of microbial transglutaminase to reduce egg protein allergenicity

Read More  

EMCAPE (2011)

Evaluating Aerobic Microbial Methane Cycling under Archaean-Proterozoic Environmental Conditions

Read More  

FIBROGELNET (2013)

Network for Development of Soft Nanofibrous Construct for Cellular Therapy of Degenerative Skeletal Disorders

Read More